Dobrucki Lawrence W, Sinusas Albert J
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8017, USA.
Semin Nucl Med. 2005 Jan;35(1):73-81. doi: 10.1053/j.semnuclmed.2004.09.006.
The recent introduction of novel gene therapies for treatment of cardiac and noncardiac diseases has caused a remarkable need for noninvasive imaging approaches to evaluate and track the progress of these therapies. In the past we have relied on the evaluation of the physiological consequences of therapeutic interventions. With advances in targeted molecular imaging we now have the ability to evaluate early molecular effects of these therapies. The development of dedicated high resolution small animal imaging systems and the establishment of transgenic animal models has enhanced our understanding of cardiovascular disease and has expedited the development of new gene therapies. Noninvasive targeted molecular imaging will allow us to directly track biochemical processes and signaling events that precede the pathophysiological changes. The examples of targeted molecular imaging outlined in this seminar provide some insight into the bright and growing future of cardiovascular molecular imaging. The success of this new field rests on the development of targeted biological markers of molecular and physiological processes, development of new instruments with improved sensitivity and resolution, and the establishment of multidisciplinary teams of experimental and clinical investigators with a wide range of expertise. Molecular imaging already plays a critical role in the experimental laboratory. We expect that, in the near future, targeted molecular imaging will be routinely used in clinical cardiovascular nuclear medicine laboratories in conjunction with existing imaging modalities for both diagnostic and prognostic purposes, as well as for evaluation of new genetic based therapeutic strategies.
最近用于治疗心脏疾病和非心脏疾病的新型基因疗法的出现，引发了对非侵入性成像方法的显著需求，以评估和跟踪这些疗法的进展。过去，我们依赖于对治疗干预的生理后果进行评估。随着靶向分子成像技术的进步，我们现在有能力评估这些疗法的早期分子效应。专用高分辨率小动物成像系统的开发以及转基因动物模型的建立，加深了我们对心血管疾病的理解，并加速了新基因疗法的开发。非侵入性靶向分子成像将使我们能够直接跟踪在病理生理变化之前发生的生化过程和信号事件。本次研讨会中概述的靶向分子成像实例，为心血管分子成像光明且不断发展的未来提供了一些见解。这个新领域的成功取决于分子和生理过程靶向生物标志物的开发、具有更高灵敏度和分辨率的新仪器的开发，以及组建由具有广泛专业知识的实验和临床研究人员组成的多学科团队。分子成像已经在实验实验室中发挥着关键作用。我们预计，在不久的将来，靶向分子成像将与现有的成像方式一起，常规用于临床心血管核医学实验室，用于诊断和预后目的，以及评估基于新基因的治疗策略。
